THE LANCET, Vol 355, February 26, 2000 George Perry, Akihiko Nunomura, Arun K Raina, Mark A Smith View Poster Post navigationPreviousPrevious post:Sigma-1 receptor ligand 4-phenyl-1-(4-phenylbutyl)-piperidine affords neuroprotection from focal ischemia with prolonged reperfusion.NextNext post:Neuroactive neurosteroids as endogenous effectors for the sigma1 (σ1) receptor: Pharmacological evidence and therapeutic opportunities.Related PostsAnavex Life Sciences to Present at the 30th Annual ROTH ConferenceMarch 9, 2018Anavex Life Sciences to Present New Preclinical Data at the 20th Annual Meeting of the American Society for Experimental Neurotherapeutics (ASENT)March 7, 2018Anavex Life Sciences to Present at Cowen and Company 38th Annual Health Care ConferenceMarch 6, 2018Anavex Life Sciences Strengthens Management Team and Board of DirectorsMarch 5, 2018
Anavex Life Sciences to Present New Preclinical Data at the 20th Annual Meeting of the American Society for Experimental Neurotherapeutics (ASENT)March 7, 2018
